Skip to content

Download our latest eBook on lung airway epithelial cell and fibroblast models

Updates - Page 3

Retinal organoids
28th April, 2022

Retinal Organoids for Drug Discovery

Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…

Read update
Glomerulus surrounded by convoluted tubules
11th March, 2022

Why is an in vitro model of the glomerulus desperately needed?

In most cases, once the kidney’s function is limited, the only treatment options are dialysis and kidney transplant. The absence of effective drugs to treat kidney disease is partly…

Read update
How to reduce drug attrition during drug development
1st February, 2022

How to reduce drug attrition during drug development?

There are two main causes of drug attrition: safety and efficacy, and in both instances, the common denominator is the inadequacy of current preclinical models to predict outcomes in…

Read update
Dr Kathryn Garner, PhD
17th January, 2022

Dr Kathryn Garner, Head of Kidney Development at NB

As she narrates her story, you have the impression that you have made the journey with her, her words becoming rich images in…

Read update
Newcells Biotech
5th November, 2021

iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery

What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…

Read update
Case study placeholder image
25th October, 2021

In vitro models for chronic kidney disease (CKD)

Phosphate balance is central to many metabolic pathways, and the kidneys play a key role in the reabsorption and excretion of phosphate to achieve this balance. In CKD, however,…

Read update
Thought Leadership workshop hosted by Newcells Biotech
18th August, 2021

Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications

These include the first oligonucleotide-based therapies (Spinraza, Exondys, Vyondys), in vivo gene therapies (Luxturna and Zolgensma) and the first cell therapies (Kymriah, Yescarta, Tescartus). Such novel therapeutics treat disorders varying…

Read update
Lung Model
3rd August, 2021

Lung epithelium in vitro modelling of SARS-CoV2 infections to aid Covid-19 treatments

Newcells Biotech’s team has developed a state-of-the-art iPSC-derived in vitro model of the human upper airway to accelerate the development of novel treatments against Covid-19 and other respiratory…

Read update
Global scientific expertise built into every Newcells Biotech product and service
25th May, 2021

Global scientific expertise built into every NB product & service

At Newcells Biotech, we build our Industry leading scientific expertise and technical excellence into all the products and services we offer to our customers, delivering innovative solutions for drug…

Read update
An experiment being carried out
13th April, 2021

NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study

Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…

Read update
3d lung airway model
30th March, 2021

Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing

Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded 

Read update
Two mice
25th February, 2021

Our commitment to the 3Rs

There are few topics more controversial than the use of animals in science, despite the enormous contribution animal experimentation continues to make to the development of new medicines and…

Read update

Get our latest updates straight to your inbox